Fluoroquinolone resistance associated with target mutations and active efflux in orophalyngeal colonizing isolates of viridans group streptococci

被引:36
作者
Guerin, F
Varon, E
Hoï, AB
Gutmann, L
Podglajen, I
机构
[1] Univ Paris 06, LRMA, F-75270 Paris 06, France
[2] Hop Broussais, Microbiol Serv, F-75674 Paris, France
关键词
D O I
10.1128/AAC.44.8.2197-2200.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Oropharyngeal samples from 60 hospitalized patients (30 fluoroquinolone [FQ]-treated and 30 non-FQ-treated patients) and 30 untreated nonhospitalized healthy control subjects yielded 20 isolates of viridans group streptococci with reduced susceptibility to FQ, mostly from the hospitalized patients. An efflux phenotype was commonly encountered, expressed either alone or with topoisomerase mutations, Interspecies transfer of the efflux phenotype was demonstrated via transformation of Streptococcus pneumoniae R6 with DNA from S. mitis and S, oralis.
引用
收藏
页码:2197 / 2200
页数:4
相关论文
共 21 条
[1]  
Ausubel FM., 1998, CURRENT PROTOCOLS MO
[2]   Molecular characterization of the gene encoding the DNA gyrase a subunit of Streptococcus pneumoniae [J].
Balas, D ;
Fernández-Moreira, E ;
De la Campa, AG .
JOURNAL OF BACTERIOLOGY, 1998, 180 (11) :2854-2861
[3]   Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae [J].
Brenwald, NP ;
Gill, MJ ;
Wise, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) :2032-2035
[4]   Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada [J].
Chen, DK ;
McGeer, A ;
de Azavedo, JC ;
Low, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (04) :233-239
[5]   Drug efflux and parC mutations are involved in fluoroquinolone resistance in viridans group streptococci [J].
Ferrándiz, MJ ;
Oteo, J ;
Aracil, B ;
Gómez-Garcés, JL ;
de la Campa, AG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (10) :2520-2523
[6]   Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus:: Novel pleiotropic effects an quinolone and coumarin activity [J].
Fournier, B ;
Hooper, DC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (01) :121-128
[7]   Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae [J].
Gill, MJ ;
Brenwald, NP ;
Wise, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (01) :187-189
[8]   Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci [J].
González, I ;
Georgiou, M ;
Alcaide, F ;
Balas, D ;
Liñares, J ;
De la Campa, AG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) :2792-2798
[9]   Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong [J].
Ho, PL ;
Que, TL ;
Tsang, DNC ;
Ng, TK ;
Chow, KH ;
Seto, WH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) :1310-1313
[10]   In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S-mitis [J].
Janoir, C ;
Podglajen, I ;
Kitzis, MD ;
Poyart, C ;
Gutmann, L .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (02) :555-558